Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predicting paclitaxel-induced neutropenia using the DMET platform.
Nieuweboer AJ, Smid M, de Graan AJ, Elbouazzaoui S, de Bruijn P, Martens JW, Mathijssen RH, van Schaik RH. Nieuweboer AJ, et al. Among authors: elbouazzaoui s. Pharmacogenomics. 2015;16(11):1231-41. doi: 10.2217/pgs.15.68. Epub 2015 Aug 12. Pharmacogenomics. 2015. PMID: 26265135
Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics.
Nieuweboer AJ, Smid M, de Graan AM, Elbouazzaoui S, de Bruijn P, Eskens FA, Hamberg P, Martens JW, Sparreboom A, de Wit R, van Schaik RH, Mathijssen RH. Nieuweboer AJ, et al. Among authors: elbouazzaoui s. Pharmacogenomics J. 2016 Nov;16(6):519-524. doi: 10.1038/tpj.2015.66. Epub 2015 Sep 8. Pharmacogenomics J. 2016. PMID: 26345519
A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform.
de Graan AJ, Elens L, Smid M, Martens JW, Sparreboom A, Nieuweboer AJ, Friberg LE, Elbouazzaoui S, Wiemer EA, van der Holt B, Verweij J, van Schaik RH, Mathijssen RH. de Graan AJ, et al. Among authors: elbouazzaoui s. Clin Cancer Res. 2013 Sep 15;19(18):5210-7. doi: 10.1158/1078-0432.CCR-13-0487. Epub 2013 Aug 5. Clin Cancer Res. 2013. PMID: 23918604
The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer.
Belderbos BPS, de With M, Singh RK, Agema BC, El Bouazzaoui S, Oomen-de Hoop E, de Wit R, van Schaik RHN, Mathijssen RHJ, Bins S. Belderbos BPS, et al. Cancer Chemother Pharmacol. 2020 Mar;85(3):547-553. doi: 10.1007/s00280-019-04011-0. Epub 2020 Jan 1. Cancer Chemother Pharmacol. 2020. PMID: 31893292 Clinical Trial.
Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer.
Hurkmans DP, Basak EA, Schepers N, Oomen-De Hoop E, Van der Leest CH, El Bouazzaoui S, Bins S, Koolen SLW, Sleijfer S, Van der Veldt AAM, Debets R, Van Schaik RHN, Aerts JGJV, Mathijssen RHJ. Hurkmans DP, et al. J Immunother Cancer. 2020 May;8(1):e000586. doi: 10.1136/jitc-2020-000586. J Immunother Cancer. 2020. PMID: 32461348 Free PMC article.
DPYD*7 as a Predictor of Severe Fluoropyrimidine-Related Adverse Events.
de With M, Brufau G, van den Berg LA, de Man FM, Trajkovic M, Thijs MF, Castel R, Vermeer HJ, El Bouazzaoui S, van Hemel A, Matic M, Mathijssen RHJ, Bins S, van Schaik RHN. de With M, et al. JCO Precis Oncol. 2022 Jul;6:e2200180. doi: 10.1200/PO.22.00180. JCO Precis Oncol. 2022. PMID: 35862869
15 results